JNJ vs ABBV
By Alex · Tickerpine
Johnson & Johnson vs AbbVie Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | ABBV |
|---|---|---|
| Price | $285.75 | $295.03 |
| Market cap | $687.89B | $521.50B |
| P/E ratio | 43.4 | 50.7 |
| ROE | 20.02% | — |
| Profit margin | 16.20% | 15.67% |
| Revenue growth | 5.90% | 10.30% |
| Dividend yield | 1.88% | 2.35% |
| Beta | 0.20 | 0.19 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs ABBV in plain English
- JNJ is the bigger company — about 1.3× the market cap of ABBV.
- JNJ is cheaper on earnings (P/E 43.4 vs 50.7).
- ABBV is growing revenue faster (10% vs 6%).
- ABBV has the higher dividend yield (2.35% vs 1.88%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.